AT505478T - Molecular mimetics of meningococales b epitopes - Google Patents

Molecular mimetics of meningococales b epitopes

Info

Publication number
AT505478T
AT505478T AT05077575T AT05077575T AT505478T AT 505478 T AT505478 T AT 505478T AT 05077575 T AT05077575 T AT 05077575T AT 05077575 T AT05077575 T AT 05077575T AT 505478 T AT505478 T AT 505478T
Authority
AT
Austria
Prior art keywords
meningococales
epitopes
molecular mimetics
mimetics
molecular
Prior art date
Application number
AT05077575T
Other languages
German (de)
Inventor
Dan M Granoff
Gregory R Moe
Original Assignee
Novartis Vaccines & Diagnostic
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5800197P priority Critical
Application filed by Novartis Vaccines & Diagnostic, Childrens Hosp Medical Center filed Critical Novartis Vaccines & Diagnostic
Publication of AT505478T publication Critical patent/AT505478T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1221Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Brucella (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245Escherichia (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
AT05077575T 1997-08-27 1998-08-26 Molecular mimetics of meningococales b epitopes AT505478T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US5800197P true 1997-08-27 1997-08-27

Publications (1)

Publication Number Publication Date
AT505478T true AT505478T (en) 2011-04-15

Family

ID=22014048

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05077575T AT505478T (en) 1997-08-27 1998-08-26 Molecular mimetics of meningococales b epitopes
AT98943399T AT421527T (en) 1997-08-27 1998-08-26 Molecular mimetics of meningococks b epitopes

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98943399T AT421527T (en) 1997-08-27 1998-08-26 Molecular mimetics of meningococks b epitopes

Country Status (12)

Country Link
US (1) US6030619A (en)
EP (2) EP1630168B1 (en)
JP (2) JP4295431B2 (en)
AT (2) AT505478T (en)
AU (1) AU9120898A (en)
CA (1) CA2301942C (en)
CY (2) CY1108897T1 (en)
DE (2) DE69840508D1 (en)
DK (1) DK1007546T3 (en)
ES (1) ES2319939T3 (en)
PT (2) PT1007546E (en)
WO (1) WO1999010372A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
EP0939647B2 (en) * 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
DE60235155D1 (en) * 2001-04-17 2010-03-11 Childrens Hosp Oak Res Inst Monoclonal antibodies to molecular mimetics of meningokoken b epitopes
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp Adjuvant compositions.
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
AT348633T (en) * 2002-07-05 2007-01-15 Lipoxen Technologies Ltd Method for reinforcing an immune response of nucleic acid vaccination
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP1784428A2 (en) 2004-06-23 2007-05-16 Children's Hospital & Research Center at Oakland Polysaccharide derivatives and uses in induction of an immune response
US20070003954A1 (en) * 2005-05-12 2007-01-04 The Board Of Regents Of The University Of Texas System Protein and antibody profiling using small molecule microarrays
AR058736A1 (en) * 2005-12-29 2008-02-20 Ct Ingenieria Genetica Biotech Carbohydrate mimetic peptides and their use in pharmaceutical formulations
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp Polynucleotide vector that comprises recombinant cell comprising the vector polypeptide, antibody, composition comprising the polynucleotide, vector, polypeptide or antibody recombinant cell, using the composition and method for preparing the same composition and prepare a composi
JP2011506334A (en) 2007-12-07 2011-03-03 ノバルティス アーゲー Composition for inducing an immune response
CA2733943A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
KR20120120185A (en) * 2009-12-22 2012-11-01 셀덱스 쎄라퓨틱스, 인크. Vaccine compositions
KR101594228B1 (en) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
ES2585328T3 (en) 2010-09-10 2016-10-05 Wyeth Llc Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
PE20190458A1 (en) 2012-03-09 2019-04-01 Pfizer Neisseria meningitidis compositions and methods thereof
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
JP5698693B2 (en) * 2012-03-13 2015-04-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Serum bactericidal assay for meningococcal specific antiserum
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
KR20190112081A (en) 2017-01-31 2019-10-02 화이자 인코포레이티드 Neisseria meningitidis composition and method thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA8101368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DK518384A (en) 1984-01-31 1985-07-01 Idaho Res Found Vector for the production of a gene product in insect cells, process for its preparation and its use
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
AT135397T (en) 1988-09-23 1996-03-15 Cetus Oncology Corp Cell culture medium for enhanced cell growth, to increase the longevity and expression of products
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla New strain and mutants of filamentous fungi, recombinant protein production process using said strain, and strains and proteins obtained according to such process
KR0158436B1 (en) * 1989-12-14 1998-12-01 피에르 오. 페론 Improved meningococcal polysaccharide conjugate vaccine
FR2667864B2 (en) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derivatives of n-phenyl glycinamides, their preparation and medicines containing them.
JP2631035B2 (en) * 1991-03-12 1997-07-16 アメリカ合衆国 Polysaccharide - protein complexes
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Immunogenic detoxified mutants of cholera toxin and the toxin lt, their preparation and use for the preparation of vaccines
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
WO1998008874A1 (en) 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Also Published As

Publication number Publication date
CY1108897T1 (en) 2014-07-02
EP1007546A1 (en) 2000-06-14
JP2001514187A (en) 2001-09-11
DE69840508D1 (en) 2009-03-12
CA2301942C (en) 2011-05-31
US6030619A (en) 2000-02-29
PT1630168E (en) 2011-07-20
EP1630168A3 (en) 2006-09-13
ES2319939T3 (en) 2009-05-14
AU9120898A (en) 1999-03-16
WO1999010372A1 (en) 1999-03-04
JP4295431B2 (en) 2009-07-15
EP1630168A2 (en) 2006-03-01
EP1007546B1 (en) 2009-01-21
DE69842224D1 (en) 2011-05-26
CY1113202T1 (en) 2016-04-13
EP1630168B1 (en) 2011-04-13
AT421527T (en) 2009-02-15
DK1007546T3 (en) 2009-03-16
JP2009143944A (en) 2009-07-02
PT1007546E (en) 2009-04-24
CA2301942A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
DE69923309D1 (en) Fractionation
DE69942072D1 (en) Telomerase-derived antigenic peptides
DE69830504D1 (en) Antitromombotic means
DE69733649D1 (en) Calcylitic compounds
DE69732184D1 (en) Lining
FR2763699B1 (en) Opto-sensor
DE69832369D1 (en) hemofiltration
DE69738398D1 (en) Biokeramic composition
DE69839309D1 (en) Video rectoscope
DK0988412T3 (en) Covering
DK1298194T3 (en) Staniol-containing compositions
DE69837136D1 (en) Optimized routing
DE69836667D1 (en) Audio-video-synchronized player
DE69635088T2 (en) neutrokin alpha
DK1015586T3 (en) TIE receptortyrosinkinaseligandhomologer
DK1270725T3 (en) anticalins
DE69739832D1 (en) Nähfadenankeranordnung
DK0901474T3 (en) Arylpyrimidinderivater
DE69736781D1 (en) Implantierungsinstrument
DE69737998D1 (en) Abgabevorrichting
DE69739032D1 (en) Bandfixiervorrichtung
DE69734457D1 (en) Reaktionsgefaesse
DE69738275D1 (en) Aminoindanderivate
DE69831181D1 (en) location
DK0958018T3 (en) Legetöjsbyggesætsystem

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties